Abbott ABT announced
today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics,
Inc. PCYC to explore the benefits of Abbott's proprietary FISH (fluorescence in
situ hybridization) technology for use in developing a molecular companion
diagnostic test to identify patients with a genetic subtype of chronic
lymphocytic leukemia (CLL), the most common form of adult leukemia.
Under the agreement, Abbott will develop a FISH-based test to identify
high-risk CLL patients who have a deletion within a specific chromosome
(chromosome 17p (del17p)) and may respond to ibrutinib, an oral, small
molecule inhibitor of Bruton tyrosine kinase (BTK). Ibrutinib is currently in
development by Janssen and Pharmacyclics for several B-cell malignancies,
including chronic leukemia and lymphoma. Patients harboring a deletion within
chromosome 17p are poor responders to chemoimmunotherapy and have limited
treatment options. Having a test that is able to accurately detect the 17p
deletion identifies a specific patient population with a high unmet medical
need.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in